Status:
COMPLETED
Evaluation of Fibromyalgia Syndrome and Its Effect on Quality of Life in Rheumatoid Arthritis
Lead Sponsor:
Ahi Evran University Education and Research Hospital
Conditions:
Rheumatoid Arthritis
Fibromyalgia
Eligibility:
All Genders
18-65 years
Brief Summary
Rheumatoid arthritis is a chronic, autoimmune, systemic inflammatory disease with a prevalence of approximately 1%. With a lifetime development rate of 3.6%, rheumatoid arthritis is seen 1.7% more in ...
Detailed Description
Rheumatoid arthritis is a chronic, autoimmune, systemic inflammatory disease with a prevalence of approximately 1%. With a lifetime development rate of 3.6%, rheumatoid arthritis is seen 1.7% more in ...
Eligibility Criteria
Inclusion
- diagnosed with rheumatoid arthritis,
- who can read and write in Turkish,
- participant's admission participating in the study,
- participants who do not have exclusion criteria
Exclusion
- participant's refusal to participate in the study,
- lack of cooperation due to cognitive impairment,
- participant's who have a neurological disease,
- presence of drug abuse,
- presence of malignancy in any organ or system,
- serious psychiatric problems (psychosis, etc.),
- the presence of another rheumatological disease other than Rheumatoid Arthritis,
- serious and unstable metabolic disease.
Key Trial Info
Start Date :
April 1 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
November 30 2022
Estimated Enrollment :
85 Patients enrolled
Trial Details
Trial ID
NCT04813549
Start Date
April 1 2021
End Date
November 30 2022
Last Update
February 8 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Kirsehir Ahi Evran University Hospital
Kırşehir, Turkey (Türkiye)